Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome
Primary Purpose
Irritable Bowel Syndrome
Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
low FODMAPs
Sponsored by
About this trial
This is an interventional treatment trial for Irritable Bowel Syndrome focused on measuring Microbiota Community, FODMAPs, IBS
Eligibility Criteria
Inclusion Criteria:
- the presence of Rome III criteria for IBS ;
- Patients scheduled for colonoscopy examination or having negative screening examinations
- Aged between 18 and 65 years old
Exclusion Criteria:
- Antibiotic, probiotic or laxative usage within 4 weeks.
- organic gastrointestinal diseases
- Severe systematic disease: diabetes mellitus, hepatic, renal or cardiac dysfunction, thyroid disease or tumor etc.
- pregnancy or lactation.
- previous major or complicated abdominal surgery.
- severe endometriosis and dementia
Sites / Locations
- Department of Gastroenterology, Qilu Hospital, Shandong UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
IBS patients
healthy controls
Arm Description
eat the low FODMAPs diet for one week
eat the low FODMAPs diet for one week
Outcomes
Primary Outcome Measures
changes of symptom scores
Secondary Outcome Measures
proportion of responders
quality of life in IBS patients
microbial composition in different response to low FODMAPs
Full Information
NCT ID
NCT02565550
First Posted
September 30, 2015
Last Updated
September 30, 2015
Sponsor
Shandong University
1. Study Identification
Unique Protocol Identification Number
NCT02565550
Brief Title
Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome
Official Title
Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
September 2015
Overall Recruitment Status
Unknown status
Study Start Date
July 2015 (undefined)
Primary Completion Date
November 2015 (Anticipated)
Study Completion Date
November 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shandong University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To determine the efficacy of a low FODMAP diet in IBS patients and whether gut microbiota community is associated with its efficacy.
Detailed Description
We seek to determine whether a low FODMAPs diet decreases symptoms in irritable bowel syndrome (IBS)patients and to identify potential microbial factors related to diet efficacy. Pain symptoms, stooling characteristics, breath hydrogen, stool microbiome will be collected and/or documented in IBS patients at baseline and during one week of an low FODMAPs intervention.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome
Keywords
Microbiota Community, FODMAPs, IBS
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
90 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
IBS patients
Arm Type
Experimental
Arm Description
eat the low FODMAPs diet for one week
Arm Title
healthy controls
Arm Type
Active Comparator
Arm Description
eat the low FODMAPs diet for one week
Intervention Type
Dietary Supplement
Intervention Name(s)
low FODMAPs
Intervention Description
low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
Primary Outcome Measure Information:
Title
changes of symptom scores
Time Frame
5 months
Secondary Outcome Measure Information:
Title
proportion of responders
Time Frame
3 months
Title
quality of life in IBS patients
Time Frame
5 months
Title
microbial composition in different response to low FODMAPs
Time Frame
5 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
the presence of Rome III criteria for IBS ;
Patients scheduled for colonoscopy examination or having negative screening examinations
Aged between 18 and 65 years old
Exclusion Criteria:
Antibiotic, probiotic or laxative usage within 4 weeks.
organic gastrointestinal diseases
Severe systematic disease: diabetes mellitus, hepatic, renal or cardiac dysfunction, thyroid disease or tumor etc.
pregnancy or lactation.
previous major or complicated abdominal surgery.
severe endometriosis and dementia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yanqing Li, MD.PhD
Phone
86-531-82169236
Ext
86-531-8216923
Email
liyanqing@sdu.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yanqing Li, MD.PhD
Organizational Affiliation
Qilu Hospital of Shandong University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Gastroenterology, Qilu Hospital, Shandong University
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250012
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yanqing Li, MD.PHD
Phone
86-531-8216923
Ext
86-531-8216923
Email
liyanqing@sdu.edu.cn
First Name & Middle Initial & Last Name & Degree
Jiaxin Du, MD
12. IPD Sharing Statement
Learn more about this trial
Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome
We'll reach out to this number within 24 hrs